Earl-Slater A
Department of Medicines Management, Keele University.
Health Serv J. 1999 May 6;109(5653):18-20.
The government has proposed a statutory scheme to regulate prices and profits on the sale of drugs to the NHS. Drug companies which don't cooperate could be liable to heavy fines, but the government has failed to spell out the precise conditions under which such penalties would apply. Defining what comprises excessive prices or profits is likely to present a number of empirical problems. Experience overseas suggests that the scheme will fail to halt the inexorable rise in the NHS drugs bill.
政府已提议制定一项法定计划,以规范向国民医疗服务体系(NHS)出售药品的价格和利润。不合作的制药公司可能会面临巨额罚款,但政府尚未阐明适用此类处罚的具体条件。界定什么构成过高的价格或利润可能会带来一些实证问题。海外经验表明,该计划将无法阻止国民医疗服务体系药品费用的持续上涨。